Protalix Ev To Operating Cash Flow vs Net Income Per Share Analysis

PLX Stock

USD 2.38 0.03 1.28%

Protalix Biotherapeutics financial indicator trend analysis is much more than just breaking down Protalix Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protalix Biotherapeutics is a good investment. Please check the relationship between Protalix Biotherapeutics Ev To Operating Cash Flow and its Net Income Per Share accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Ev To Operating Cash Flow vs Net Income Per Share

Ev To Operating Cash Flow vs Net Income Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protalix Biotherapeutics Ev To Operating Cash Flow account and Net Income Per Share. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Protalix Biotherapeutics' Ev To Operating Cash Flow and Net Income Per Share is -0.04. Overlapping area represents the amount of variation of Ev To Operating Cash Flow that can explain the historical movement of Net Income Per Share in the same time period over historical financial statements of Protalix Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Protalix Biotherapeutics' Ev To Operating Cash Flow and Net Income Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Operating Cash Flow of Protalix Biotherapeutics are associated (or correlated) with its Net Income Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income Per Share has no effect on the direction of Ev To Operating Cash Flow i.e., Protalix Biotherapeutics' Ev To Operating Cash Flow and Net Income Per Share go up and down completely randomly.

Correlation Coefficient

-0.04

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ev To Operating Cash Flow

A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.

Net Income Per Share

Most indicators from Protalix Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 24.9 M in 2025, despite the fact that Discontinued Operations is likely to grow to (206.5 K).

	2022	2023	2024	2025 (projected)
Total Revenue	47.6M	65.5M	75.3M	79.1M
Depreciation And Amortization	1.1M	1.2M	1.4M	1.7M

Total Revenue Depreciation And Amortization

Protalix Biotherapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Net Debt	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Non Currrent Assets Other	Common Stock Total Equity	Other Stockholder Equity	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Other Assets	Other Liab
Total Assets		0.1	0.22	-0.23	0.77	0.61	0.93	0.1	0.13	0.32	-0.66	0.52	0.99	0.47	0.15	0.48	-0.28	-0.19	0.41	0.43	0.49	0.54	0.07	0.1	0.23	0.15
Other Current Liab	0.1		0.49	0.15	-0.25	0.37	-0.1	0.56	0.57	-0.35	-0.28	-0.09	0.04	-0.1	0.24	0.36	-0.41	0.07	-0.46	0.37	0.29	-0.36	0.1	0.55	-0.37	-0.17
Total Current Liabilities	0.22	0.49		0.53	-0.14	0.22	0.09	0.14	0.47	-0.48	-0.49	0.09	0.21	0.22	0.13	0.16	-0.57	-0.22	-0.14	0.43	0.64	-0.08	0.12	0.48	-0.35	-0.39
Net Debt	-0.23	0.15	0.53		-0.38	-0.35	-0.29	0.12	0.13	-0.19	-0.34	0.13	-0.18	-0.04	-0.33	-0.44	-0.45	-0.31	-0.3	0.29	0.16	-0.31	-0.1	0.14	-0.08	-0.57
Cash	0.77	-0.25	-0.14	-0.38		0.29	0.93	-0.35	-0.32	0.63	-0.37	0.63	0.79	0.67	-0.09	0.29	0.16	-0.1	0.7	0.07	0.34	0.65	-0.04	-0.29	0.56	0.36
Non Current Assets Total	0.61	0.37	0.22	-0.35	0.29		0.42	0.48	0.17	0.2	-0.32	0.37	0.47	0.47	0.0	0.96	-0.3	0.41	0.12	0.26	0.26	0.22	0.63	0.09	0.08	0.5
Cash And Short Term Investments	0.93	-0.1	0.09	-0.29	0.93	0.42		-0.2	-0.09	0.44	-0.51	0.56	0.95	0.6	0.08	0.35	-0.01	-0.19	0.59	0.25	0.51	0.63	-0.05	-0.1	0.32	0.21
Net Receivables	0.1	0.56	0.14	0.12	-0.35	0.48	-0.2		0.56	-0.1	-0.34	-0.03	0.01	-0.18	0.07	0.38	-0.64	0.27	-0.2	0.47	-0.2	-0.01	0.46	0.33	-0.13	0.0
Common Stock Shares Outstanding	0.13	0.57	0.47	0.13	-0.32	0.17	-0.09	0.56		-0.62	-0.42	-0.42	0.12	-0.4	0.68	0.1	-0.62	-0.27	-0.37	0.74	0.05	-0.15	-0.07	0.76	-0.6	-0.52
Non Current Liabilities Total	0.32	-0.35	-0.48	-0.19	0.63	0.2	0.44	-0.1	-0.62		-0.16	0.83	0.32	0.55	-0.71	0.21	0.13	0.14	0.57	-0.13	-0.11	0.46	0.2	-0.57	0.8	0.7
Other Current Assets	-0.66	-0.28	-0.49	-0.34	-0.37	-0.32	-0.51	-0.34	-0.42	-0.16		-0.49	-0.67	-0.29	0.01	-0.18	0.77	0.51	-0.12	-0.71	-0.29	-0.25	0.0	-0.31	-0.27	0.23
Total Liab	0.52	-0.09	0.09	0.13	0.63	0.37	0.56	-0.03	-0.42	0.83	-0.49		0.5	0.76	-0.73	0.34	-0.22	0.02	0.56	0.12	0.29	0.47	0.31	-0.34	0.69	0.55
Total Current Assets	0.99	0.04	0.21	-0.18	0.79	0.47	0.95	0.01	0.12	0.32	-0.67	0.5		0.43	0.17	0.34	-0.25	-0.3	0.43	0.43	0.49	0.56	-0.04	0.1	0.24	0.06
Short Long Term Debt Total	0.47	-0.1	0.22	-0.04	0.67	0.47	0.6	-0.18	-0.4	0.55	-0.29	0.76	0.43		-0.44	0.53	0.01	0.24	0.64	0.05	0.36	0.51	0.39	-0.4	0.49	0.48
Total Stockholder Equity	0.15	0.24	0.13	-0.33	-0.09	0.0	0.08	0.07	0.68	-0.71	0.01	-0.73	0.17	-0.44		-0.01	0.0	-0.2	-0.28	0.29	0.07	-0.11	-0.32	0.53	-0.65	-0.53
Property Plant And Equipment Net	0.48	0.36	0.16	-0.44	0.29	0.96	0.35	0.38	0.1	0.21	-0.18	0.34	0.34	0.53	-0.01		-0.17	0.51	0.12	0.17	0.23	0.17	0.65	0.03	0.07	0.58
Retained Earnings	-0.28	-0.41	-0.57	-0.45	0.16	-0.3	-0.01	-0.64	-0.62	0.13	0.77	-0.22	-0.25	0.01	0.0	-0.17		0.26	0.1	-0.76	-0.04	-0.05	-0.3	-0.57	-0.01	0.26
Non Currrent Assets Other	-0.19	0.07	-0.22	-0.31	-0.1	0.41	-0.19	0.27	-0.27	0.14	0.51	0.02	-0.3	0.24	-0.2	0.51	0.26		0.12	-0.35	-0.07	0.06	0.76	-0.21	0.06	0.52
Common Stock Total Equity	0.41	-0.46	-0.14	-0.3	0.7	0.12	0.59	-0.2	-0.37	0.57	-0.12	0.56	0.43	0.64	-0.28	0.12	0.1	0.12		-0.01	0.06	0.95	0.17	-0.46	0.52	0.48
Other Stockholder Equity	0.43	0.37	0.43	0.29	0.07	0.26	0.25	0.47	0.74	-0.13	-0.71	0.12	0.43	0.05	0.29	0.17	-0.76	-0.35	-0.01		-0.02	0.16	-0.01	0.56	-0.14	-0.36
Short Term Debt	0.49	0.29	0.64	0.16	0.34	0.26	0.51	-0.2	0.05	-0.11	-0.29	0.29	0.49	0.36	0.07	0.23	-0.04	-0.07	0.06	-0.02		0.07	0.03	0.09	-0.21	-0.07
Common Stock	0.54	-0.36	-0.08	-0.31	0.65	0.22	0.63	-0.01	-0.15	0.46	-0.25	0.47	0.56	0.51	-0.11	0.17	-0.05	0.06	0.95	0.16	0.07		0.16	-0.33	0.4	0.38
Accounts Payable	0.07	0.1	0.12	-0.1	-0.04	0.63	-0.05	0.46	-0.07	0.2	0.0	0.31	-0.04	0.39	-0.32	0.65	-0.3	0.76	0.17	-0.01	0.03	0.16		0.05	0.22	0.5
Short Term Investments	0.1	0.55	0.48	0.14	-0.29	0.09	-0.1	0.33	0.76	-0.57	-0.31	-0.34	0.1	-0.4	0.53	0.03	-0.57	-0.21	-0.46	0.56	0.09	-0.33	0.05		-0.41	-0.47
Other Assets	0.23	-0.37	-0.35	-0.08	0.56	0.08	0.32	-0.13	-0.6	0.8	-0.27	0.69	0.24	0.49	-0.65	0.07	-0.01	0.06	0.52	-0.14	-0.21	0.4	0.22	-0.41		0.45
Other Liab	0.15	-0.17	-0.39	-0.57	0.36	0.5	0.21	0.0	-0.52	0.7	0.23	0.55	0.06	0.48	-0.53	0.58	0.26	0.52	0.48	-0.36	-0.07	0.38	0.5	-0.47	0.45

Click cells to compare fundamentals

Protalix Biotherapeutics Account Relationship Matchups

Protalix Biotherapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	67.9M	73.7M	55.8M	84.4M	97.1M	51.0M
Other Current Liab	13.9M	15.2M	10.6M	15.3M	17.6M	18.4M
Total Current Liabilities	86.5M	33.2M	32.4M	45.5M	52.4M	55.0M
Net Debt	46.1M	(5.5M)	16.4M	2.6M	3.0M	3.2M
Cash	18.3M	39.0M	17.1M	23.6M	27.2M	31.8M
Non Current Assets Total	12.2M	12.0M	10.9M	14.5M	16.7M	9.6M
Cash And Short Term Investments	38.5M	39.0M	22.2M	44.6M	51.2M	33.7M
Net Receivables	2M	3.4M	4.6M	5.3M	6.1M	3.1M
Common Stock Shares Outstanding	29.1M	44.1M	48.5M	82.4M	94.8M	99.5M
Liabilities And Stockholders Equity	67.9M	73.7M	55.8M	84.4M	97.1M	51.0M
Non Current Liabilities Total	8.5M	46.5M	34.0M	5.3M	6.1M	5.8M
Other Current Assets	2.1M	1.3M	1.3M	1.1M	949.5K	1.6M
Total Liab	95.0M	79.7M	66.4M	50.9M	58.5M	56.1M
Total Current Assets	55.7M	61.7M	44.9M	69.9M	80.4M	42.5M
Short Long Term Debt Total	64.4M	33.5M	33.5M	26.3M	30.2M	51.9M
Total Stockholder Equity	(27.0M)	(6.0M)	(10.6M)	33.6M	30.2M	31.7M
Property Plant And Equipment Net	10.4M	9.9M	9.6M	10.9M	12.5M	10.5M
Retained Earnings	(347.4M)	(374.9M)	(389.9M)	(381.5M)	(343.4M)	(326.2M)
Non Currrent Assets Other	1.8M	2.1M	1.3M	528K	607.2K	576.8K
Other Stockholder Equity	320.3M	368.9M	379.2M	415.0M	477.3M	501.2M
Short Term Debt	59.9M	2.4M	2.2M	23.1M	26.5M	18.6M
Common Stock	35K	46K	54K	73K	84.0K	62.8K
Accounts Payable	7.2M	7.0M	5.9M	4.3M	5.0M	4.3M
Short Term Investments	20.3M	39.0M	5.1M	20.9M	24.1M	25.3M
Other Assets	7.4K	2.1M	1.3M	1.0	1.15	1.09
Other Liab	20.1M	4.0M	14.3M	1.6M	1.5M	1.4M
Property Plant Equipment	5.3M	10.4M	9.9M	9.6M	8.7M	8.1M
Current Deferred Revenue	5.4M	8.6M	13.2M	2.9M	3.3M	3.1M
Inventory	13.1M	18.0M	16.8M	19.0M	21.9M	23.0M
Net Tangible Assets	(70.3M)	(27.0M)	(6.0M)	(10.6M)	(9.6M)	(10.1M)
Long Term Debt	51.0M	51K	27.9M	28.2M	25.4M	28.8M
Capital Surpluse	270.5M	320.3M	368.9M	379.2M	436.0M	272.0M
Property Plant And Equipment Gross	10.4M	9.9M	9.6M	45.6M	52.4M	55.0M
Long Term Debt Total	51.5M	51K	27.9M	28.2M	25.4M	28.3M
Net Invested Capital	31.5M	21.9M	17.5M	53.8M	61.9M	65.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protalix Ev To Operating Cash Flow vs Net Income Per Share Analysis

Ev To Operating Cash Flow vs Net Income Per Share

Ev To Operating Cash Flow vs Net Income Per Share Correlation Analysis

Correlation Coefficient

Ev To Operating Cash Flow

Net Income Per Share

Protalix Biotherapeutics fundamental ratios Correlations

Protalix Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protalix Biotherapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Protalix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.96	Non Current Assets Total
Total Current Assets	+ 0.95	Cash And Short Term Investments
Common Stock	+ 0.95	Common Stock Total Equity
Cash And Short Term Investments	+ 0.93	Total Assets
Cash And Short Term Investments	+ 0.93	Cash

Other Stockholder Equity	- 0.76	Retained Earnings
Total Stockholder Equity	- 0.73	Total Liab
Other Stockholder Equity	- 0.71	Other Current Assets
Total Stockholder Equity	- 0.71	Non Current Liabilities Total
Total Current Assets	- 0.67	Other Current Assets
Other Current Assets	- 0.66	Total Assets